The Transplantation Research Immunology Group (TRIG) was a consortium partner in TRIAD, an EU funded project which led to the preclinical development of the novel drug FR104. The drug is now going through clinical trials, leading, it is hoped, to eventual commercialisation.
Taking targeted autoimmune therapies to the next level
- 28 July 2015
The TRIAD project has been featured on the HORIZON 2020 website in an article entitled 'Taking targeted autoimmune therapies to the next level.'